Evidence map›Paper›PMID 31040711›Full record

ArticleInternational journal of general medicine2019

Adherence, satisfaction, and experience with metformin 500 mg prolonged release formulation in Indian patients with type 2 diabetes mellitus: a postmarketing observational study.

K M Prasanna Kumar, Manoj Chawla, Ami Sanghvi, Nadiminty G Sastry, Chaitanya Kotla, Sanjeev Phatak, Sanjay Choudhari

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of general medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

K M Prasanna KumarCentre for Diabetes and Endocrine Care, Bangalore, Karnataka, India, dr.kmpk@gmail.com.
Manoj ChawlaLina Diabetes Care and Mumbai Diabetes Research Centre, Mumbai, Maharashtra, India.
Ami SanghviSanghvi Eye and Diabetes Care Centre, Mumbai, Maharashtra, India.
Nadiminty G SastryDr. Mohan's Diabetes Centre, Hyderabad, Telangana, India.
Chaitanya KotlaJP Endocrine and Research Institute, Hyderabad, Telangana, India.
Sanjeev PhatakVijayratna Diabetes Diagnosis and Treatment, Ahmedabad, India.
Sanjay ChoudhariAbbott Healthcare Pvt. Ltd., Mumbai, Maharashtra, India.
Abbott (India) · INBangalore Diabetes Centre · INDiabetes Care and Research Foundation · INDr. Kovil's Diabetes Care Centre · INDr. Mohan's Diabetes Specialities Centre · INSwasthya Diabetes Care · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to understand patient adherence, satisfaction, and experience with the smaller sized metformin 500 mg prolonged release (PR) tablet that has been manufactured with the help of technological advancement (Gluformin I 500 mg), in comparison with metformin 500 mg extended-release (ER) tablet, in patients with type 2 diabetes mellitus (T2DM). PATIENTS AND

methodsIn this postmarketing observational study, T2DM patients who were on a stable dose of metformin 500 mg PR tablet for at least 1 month and had previously received metformin 500 mg ER tablet were recruited from 50 sites in India. The medication adherence and patients' experience, satisfaction, and perception with metformin 500 mg PR tablets were compared with metformin 500 mg ER tablets. The patients' experience was determined based on the external appearance of tablet, ease of swallowing, the presence of gastrointestinal discomfort, and ghost pill effect.

resultsA total of 1,000 patients were enrolled. The majority had medium adherence to metformin 500 mg PR tablet (54%) and did not report swallowing difficulties (66.2%) due to its small size (64.4%) and oval shape (64.3%). The PR formulation of metformin was more acceptable than ER formulation due to no aftertaste (63%). The ghost pill effect was reported in 0.7% of patients with metformin 500 mg PR tablet against 8.5% with ER tablet. More than 60% of patients were "comfortable" (67.9%), had "much effect on their well-being" (61.8%), and were "satisfied" (69%) with metformin 500 mg PR tablet compared with ER tablet. Patient's dissatisfaction (42.7%) and taste (24.9%) were the common reasons cited by physicians and patients, respectively, for changing the treatment from metformin 500 mg ER to metformin 500 mg PR formulation. A total of 10 adverse events (nonserious) were reported, and all of them were resolved.

conclusionThe technologically advanced formulation of metformin 500 mg PR tablets is more effective than that of metformin 500 mg ER tablets in improving adherence, compliance, satisfaction, and perception to medication in Indian patients with T2DM.

Indexed as

abdominal discomfortmedication adherencemetformin prolonged release tabletnoncompliancetreatment satisfactiontype 2 diabetes mellitus

Identifiers

PMID31040711
PMCPMC6460999
OpenAlexW2939225988

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.